상세 보기
Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial
- Shin, Junghoon;
- Park, Sehhoon;
- Kim, Kyung Hwan;
- Shin, Eui-Cheol;
- Jung, Hyun Ae;
- ... Cho, Jong Ho;
- ... Sun, Jong-Mu;
- ... Lee, Se-Hoon;
- ... Choi, Yong Soo;
- ... Ahn, Jin Seok;
- ... Kim, Hong Kwan;
- ... Noh, Jae Myoung;
- ... Pyo, Hongryull;
- 외 5명
WEB OF SCIENCE
4초록
Purpose Optimal treatment for stage IIIA/N2 non-small cell lung cancer (NSCLC) is controversial. We aimed to assess the efficacy and safety of adjuvant pembrolizumab for stage IIIA/N2 NSCLC completely resected after neoadjuvant concurrent chemoradiation therapy (CCRT). Materials and Methods In this open-label, single-center, single-arm phase 2 trial, patients with stage IIIA/N2 NSCLC received adjuvant pembrolizumab for up to 2 years after complete resection following neoadjuvant CCRT. The primary endpoint was disease-free survival (DFS). Secondary endpoints included overall survival (OS) and safety. As an exploratory biomarker analysis, we evaluated the proliferative response of blood CD39+PD-1(+)CD8(+) T cells using fold changes in the percentage of proliferating Ki-67(+) cells from days 1 to 7 of cycle 1 (Ki-67(D7/D1)). Results Between October 2017 and October 2018, 37 patients were enrolled. Twelve (32%) and three (8%) patients harbored EGFR and ALK alterations, respectively. Of 34 patients with programmed cell death ligand 1 assessment, 21 (62%), nine (26%), and four (12%) had a tumor proportion score of < 1%, 1%-50%, and >= 50%, respectively. The median follow-up was 71 months. The median DFS was 22.4 months in the overall population, with a 5-year DFS rate of 29%. The OS rate was 86% at 2 years and 76% at 5 years. Patients with tumor recurrence within 6 months had a significantly lower Ki-67(D7/D1) among CD39(+)PD-1(+)CD8(+) T cells than those without (p=0.036). No new safety signals were identified. Conclusion Adjuvant pembrolizumab may offer durable disease control in a subset of stage IIIA/N2 NSCLC patients after neoadjuvant CCRT and surgery.
키워드
- 제목
- Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial
- 저자
- Shin, Junghoon; Park, Sehhoon; Kim, Kyung Hwan; Shin, Eui-Cheol; Jung, Hyun Ae; Cho, Jong Ho; Sun, Jong-Mu; Lee, Se-Hoon; Choi, Yong Soo; Ahn, Jin Seok; Kim, Jhingook; Park, Keunchil; Shim, Young Mog; Kim, Hong Kwan; Noh, Jae Myoung; Ahn, Yong Chan; Pyo, Hongryull; Ahn, Myung-Ju
- 발행일
- 2024-10
- 유형
- Article
- 권
- 56
- 호
- 4
- 페이지
- 1084 ~ 1095
- 언어
- ENG
- 출판사
- 대한암학회
- 발행국가
- 대한민국
- 분량
- 12 페이지
- ISSN
- E 2005-9256
P 1598-2998